Medtronic's SynchroMed pump hit by second Class I recall; fights it out with NuVasive over spinal patents
This article was originally published in Clinica
The US FDA has designated Medtronic's alert about a potential defect with the batteries in its SynchroMed II implantable drug infusion pump as a Class I recall. This is the latest in a growing list of warnings and recalls linked to the device over the last few years, and involves the same problem that Medtronic encountered in July 2009.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.